Early-Stage Drug R&D · Translational Medicine · Bioinformatics Evidence Generation
Early-Stage Drug R&D and Translational Evidence, Powered by Bioinformatics
DeepTrans Bio helps biotech, pharma, CRO, and hospital research teams turn biomedical data and research questions into structured R&D evidence packages — from target review and neoantigen prediction to biomarker analytics and omics-driven decision support.
Methods Summary
Data Sources
Known Limitations
Services
Three Tracks Aligned to Your R&D Stage
Three tracks aligned to the stages where data and analysis create the most R&D value.
Drug R&D & Project Initiation
Research support for early-stage biopharma decision-making — from landscape review to candidate prioritization.
- Project initiation & landscape research
- Target / mechanism review
- Tumor neoantigen prediction & ranking
- Competitive intelligence & candidate prioritization
Translational Medicine & Biomarker Analytics
Turn clinical and omics data into actionable evidence packages for translational research.
- Biomarker screening & ranking
- Diagnostic / risk model analysis
- Clinical cohort statistics
- Translational evidence packaging
Bioinformatics & Omics Evidence Generation
Generate structured evidence from genomic, transcriptomic, and public data sources to support R&D and translational decisions.
- NGS / RNA-seq / WES analysis
- Single-cell transcriptomics
- Public database mining (TCGA, GEO, etc.)
- Publication-ready figures & reports
Clients
Who We Help
Teams that need biomedical data interpreted, visualized, and turned into decision materials.
Biotech & Pharma Teams
Early R&D, target selection, pipeline review, and competitive intelligence.
CRO / Service Providers
Bioinformatics support, figure generation, and report preparation for client deliverables.
Hospital & Translational Researchers
Clinical cohort analysis, biomarker discovery, and translational evidence packaging.
Academic Research Groups
Publication-ready analysis, manuscript revision support, and methodology review.
Featured Work
Representative Analysis Outputs
Representative analysis outputs. Figures generated from mock or de-identified data for layout demonstration.
Biomarker Diagnostic Model
Screen candidate biomarkers and build a diagnostic scorecard with validation metrics.
View caseSingle-Cell Transcriptomics
Characterize cell-type composition and marker expression from scRNA-seq data.
View caseNeoantigen Prediction & Ranking
Rank tumor neoantigens by predicted immunogenicity and HLA binding affinity.
View case
Mendelian Randomization
Infer causal relationships between exposures and outcomes using genetic instruments.
View caseWhy DeepTrans Bio
A background that spans wet-lab research, data analysis, and R&D project management.
Wet-lab + data-analysis background
Experience in molecular biology, immunology, and computational pipelines means analysis is grounded in biological context.
Biomedical R&D context understanding
Familiar with drug discovery timelines, translational milestones, and publication requirements.
Evidence package deliverables
Outputs are designed for internal review, grant applications, manuscripts, and stakeholder presentations.
Clear boundaries and auditable outputs
Every deliverable includes methods summary, data sources, and known limitations.
R&D Decision Support
How DeepTrans Bio Supports Early-Stage R&D Decisions
Structured evidence generation for translational and drug development teams.
Target and mechanism evaluation
Literature synthesis, pathway mapping, and competitive intelligence to assess target rationale and differentiation.
Translational evidence synthesis
Integration of clinical cohort data, omics profiles, and public databases to build evidence for translational hypotheses.
Biomarker prioritization
Statistical screening, diagnostic modeling, and subgroup analysis to identify markers worth validating.
Neoantigen candidate ranking
In-silico prediction, HLA-weighted scoring, and validation-readiness assessment for immuno-oncology programs.
Competitive landscape review
Pipeline tracking, mechanism comparison, and white-space analysis to inform positioning and BD strategy.
Omics interpretation for R&D planning
NGS, single-cell, and multi-omics analysis translated into actionable R&D hypotheses and experimental recommendations.
Experimental validation-oriented insights
Every analysis is designed with the next experimental step in mind — what to test, why, and what success would look like.
How It Works
A lightweight process designed for research teams with evolving questions.
Submit project context
Share your question, available data, and expected deliverables.
Receive scope & analysis plan
DeepTrans Bio assesses fit, proposes scope, timeline, and deliverables.
Get figures, reports, and recommendations
Iterative delivery with space for feedback and refinement.
Resources
R&D Insights & Resources
Structured frameworks and evaluation guides for early-stage biomedical research. New resources added regularly.
How to Evaluate a Tumor Neoantigen Target
A framework for prioritizing neoantigen candidates before experimental validation, including scoring dimensions and decision criteria.
Translational Biomarker Evaluation Checklist
Key questions and evidence thresholds to assess whether a biomarker is ready for assay development and external validation.
Early-Stage Drug R&D Evidence Framework
A structured approach to building R&D evidence packages that support internal decisions, grant applications, and investor discussions.
Public Omics Data Interpretation Guide
Best practices for mining TCGA, GEO, and other public databases to generate hypothesis-supporting evidence for R&D programs.